![Bihua Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bihua Chen
Director/Board Member at BIOMEA FUSION, INC.
Net worth: - $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kendra Adams | F | 47 | 4 years | |
Ramses Erdtmann | M | 60 | 7 years | |
Jing Rong Cui | M | 60 |
Blossomhill Therapeutics, Inc.
![]() Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | - |
Mariam Maghribi | M | - |
Atia Vision, Inc.
![]() Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | 12 years |
Kenneth Anderson | M | 72 | 9 years | |
Tom Butler | M | 43 | 7 years | |
Bruce Downey | M | 76 | 9 years | |
Andrew Hirsch | M | 53 | 4 years | |
Claudio Argento | M | - |
Atia Vision, Inc.
![]() Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | 12 years |
Laura Bessen | M | 61 | 2 years | |
Steve Morris | M | - | 4 years | |
Vic Myer | M | - |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 4 years |
Jean Liu | F | 55 | 2 years | |
Julie Hambleton | M | 66 | 3 years | |
Elizabeth Faust | M | 59 | 2 years | |
Franco Valle | M | 43 | 3 years | |
Catherine Stehman-Breen | M | 61 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 4 years |
Malcolm Salter | M | 84 | 9 years | |
Michael Hitchcock | M | 74 | 3 years | |
Utpal Koppikar | M | 53 | 2 years | |
Jolie Siegel | F | 48 | 4 years | |
Naomi Cretcher | F | - | 17 years | |
Yi Shan Li | M | 59 |
Blossomhill Therapeutics, Inc.
![]() Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | 4 years |
Amr Salahieh | M | - |
Atia Vision, Inc.
![]() Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | - |
Owen Hughes | M | 49 | 1 years | |
Min Hua | M | 73 |
Fudan University
| 34 years |
Donna Grogan | M | 67 | 2 years | |
Sumita Ray | F | 50 | 3 years | |
Ebun Garner | M | 52 | 3 years | |
George Golumbeski | M | 67 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 2 years |
Eric Aguiar | M | 62 | 4 years | |
Nikolai Kley | M | - |
Orionis Biosciences BV
![]() Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | 9 years |
Mayra Reyes-Armour | M | - | 3 years | |
Chun Yi Zhao | M | - | 2 years | |
Thorsten Kirschberg | M | 54 | 4 years | |
Anthony Souza | M | - | 9 years | |
Hanna Cho | M | - | - | |
Priyanka Mandava | F | - | - | |
Raymond Kelleher | M | 59 |
Cormorant Asset Management LLC/Private Equity/
![]() Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 4 years |
Terrie Phan | F | - | 3 years | |
Caleb Tripp | M | 38 |
Cormorant Asset Management LLC/Private Equity/
![]() Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 3 years |
Thomas Cahill | M | - |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
Amy Grekowicz Parker | F | - | 2 years | |
Cecilia Fernandez | F | - |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
Lisa Tesvich-Bonora | M | - | 2 years | |
Shannon Morris | M | 54 | 2 years | |
Courtney Solberg | F | - | - | |
Alex Cacovean | M | - | 3 years | |
Scott Boyle | M | 46 | 2 years | |
Henry Chen | M | 53 |
Atia Vision, Inc.
![]() Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | - |
Stewart Fisher | M | 57 | 8 years | |
M. Isabel Chiu | M | - | 8 years | |
Janet Caroline Smith | F | 59 |
Putnam U.S. Holdings I LLC
![]() Putnam U.S. Holdings I LLC Investment ManagersFinance Putnam Investments LLC operates as an investment advisory company. The company was founded on May 14, 2009 and is headquartered in Boston, MA. | 23 years |
Michael Kelly | M | 67 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 1 years |
Carl Gordon | M | 59 |
Blossomhill Therapeutics, Inc.
![]() Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | - |
Kevin Bitterman | M | 47 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
Steve Gullans | M | 71 |
Orionis Biosciences BV
![]() Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | - |
George Lee | M | 73 |
Blossomhill Therapeutics, Inc.
![]() Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | - |
Brett Ilan Kaplan | M | 50 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
Kelly Schick | F | 44 | 3 years | |
Heow Tan | M | 65 | 4 years | |
Leonard Reyno | M | 62 | 1 years | |
Paola Pozzi | F | - |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
Jeffrey D. Marrazzo | M | 46 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 2 years |
Griet Vanpoucke | M | - |
Orionis Biosciences BV
![]() Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | 9 years |
Todd Sinai | M | 54 |
The Wharton School of the University of Pennsylvania
| 27 years |
Anthony Fadell | M | 55 |
Orionis Biosciences BV
![]() Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | 1 years |
Juan Frias | M | 60 | 1 years | |
Michael Zelefsky | M | 63 |
Weill Cornell Medical College
| 30 years |
Casey Gordon | M | - |
Atia Vision, Inc.
![]() Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | - |
Adrian Bignami | M | - | 3 years | |
Thomas Cahill | M | 37 |
Chroma Medicine, Inc.
![]() Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
Mark Mossler | M | 51 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Marc A. Cohen | M | 61 | 7 years | |
Andrew Phillips | M | 53 | 4 years | |
William McKee | M | 62 | 1 years | |
Yu Ming Zhang | M | 62 |
Fudan University
| 11 years |
Jason S. Fisherman | M | 67 | - | |
Lauren White | F | 45 | 2 years | |
John Schmid | M | 61 | 2 years | |
Li Jun Lin | M | 51 |
Fudan University
| 7 years |
Pranav Gupta | M | - |
The Wharton School of the University of Pennsylvania
| 13 years |
Kah Poh Tan | M | 38 | - | |
William Ogrodnick | M | - |
The Wharton School of the University of Pennsylvania
| 10 years |
Glenn Dubin | M | 67 | 3 years | |
Derrick Tang | M | - |
Cormorant Asset Management LP
![]() Cormorant Asset Management LP Investment ManagersFinance Cormorant Asset Management LLC (Cormorant) is an independent hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Bi Hua Chen in 2013. Cormorant provides discretionary investment advisory services to hedge funds, private equity funds and separately managed accounts. Investors in the Funds consist of institutional investors and other sophisticated investors. | - |
Jie Qiu Wan | M | 69 |
Fudan University
| 15 years |
Wilson Sea | M | 60 |
Fudan University
| 5 years |
Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 years |
Qing Yu Wang | M | 65 |
Fudan University
| 4 years |
Feng Yu | M | 60 |
Fudan University
| 6 years |
Xiong Wen Lu | M | 58 |
Fudan University
| 6 years |
Ken J. Ruskin | M | - |
Putnam U.S. Holdings I LLC
![]() Putnam U.S. Holdings I LLC Investment ManagersFinance Putnam Investments LLC operates as an investment advisory company. The company was founded on May 14, 2009 and is headquartered in Boston, MA. | 4 years |
Neal Rosenberg | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
John Kwon | M | 50 | - | |
Abbas M. Hasan | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
Xin Hao Jiang | M | 59 |
Fudan University
| 7 years |
Will Lewis | M | 55 | - | |
Alex Lloyd | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
Michael Robert Gelband | M | - |
Millennium Management LLC
![]() Millennium Management LLC Investment ManagersFinance Millennium Management LLC is a SEC-investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Israel 'Izzy' Englander in 1989 and is a subsidiary of MLM Trust B LLC, itself a subsidiary of MLM Trust B. Millennium Management provides discretionary investment advisory services to private investment funds. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 68 | 68.00% |
China | 9 | 9.00% |
Belgium | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bihua Chen
- Personal Network